200.33 USD
+1.92 (+0.97%)
200.33 USD
0 (0%)
Taking everything into account, LGND scores 6 out of 10 in our fundamental rating. LGND was compared to 192 industry peers in the Pharmaceuticals industry. LGND has an excellent profitability rating, but there are some minor concerns on its financial health. LGND is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! These ratings could make LGND a good candidate for growth investing.
1. Profitability
1.1 Basic Checks
In the past year LGND was profitable.
LGND had a positive operating cash flow in the past year.
In multiple years LGND reported negative net income over the last 5 years.
Each year in the past 5 years LGND had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 3.29%, LGND belongs to the top of the industry, outperforming 83.33% of the companies in the same industry.
The Return On Equity of LGND (5.11%) is better than 83.33% of its industry peers.
LGND's Return On Invested Capital of 1.58% is fine compared to the rest of the industry. LGND outperforms 78.65% of its industry peers.
LGND had an Average Return On Invested Capital over the past 3 years of 1.12%. This is significantly below the industry average of 12.85%.
The 3 year average ROIC (1.12%) for LGND is below the current ROIC(1.58%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.29% | ||
| ROE | 5.11% | ||
| ROIC | 1.58% |
ROA(3y)0.61%
ROA(5y)1.2%
ROE(3y)0.46%
ROE(5y)1.58%
ROIC(3y)1.12%
ROIC(5y)1.78%
1.3 Margins
The Profit Margin of LGND (19.34%) is better than 90.63% of its industry peers.
LGND has a better Operating Margin (11.48%) than 84.38% of its industry peers.
In the last couple of years the Operating Margin of LGND has declined.
LGND has a Gross Margin of 94.27%. This is amongst the best in the industry. LGND outperforms 95.83% of its industry peers.
LGND's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.48% | ||
| PM (TTM) | 19.34% | ||
| GM | 94.27% |
OM growth 3Y-21.5%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.37%
GM growth 5Y0.62%
2. Health
2.1 Basic Checks
LGND has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
LGND has more shares outstanding than it did 1 year ago.
The number of shares outstanding for LGND has been increased compared to 5 years ago.
The debt/assets ratio for LGND is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 5.86 indicates that LGND is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 5.86, LGND is doing good in the industry, outperforming 75.52% of the companies in the same industry.
LGND has a debt to FCF ratio of 14.48. This is a negative value and a sign of low solvency as LGND would need 14.48 years to pay back of all of its debts.
LGND has a Debt to FCF ratio of 14.48. This is in the better half of the industry: LGND outperforms 77.08% of its industry peers.
LGND has a Debt/Equity ratio of 0.47. This is a healthy value indicating a solid balance between debt and equity.
LGND has a worse Debt to Equity ratio (0.47) than 61.98% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.47 | ||
| Debt/FCF | 14.48 | ||
| Altman-Z | 5.86 |
ROIC/WACC0.17
WACC9.38%
2.3 Liquidity
A Current Ratio of 24.69 indicates that LGND has no problem at all paying its short term obligations.
LGND has a better Current ratio (24.69) than 93.75% of its industry peers.
LGND has a Quick Ratio of 24.30. This indicates that LGND is financially healthy and has no problem in meeting its short term obligations.
LGND has a Quick ratio of 24.30. This is amongst the best in the industry. LGND outperforms 92.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 24.69 | ||
| Quick Ratio | 24.3 |
3. Growth
3.1 Past
LGND shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.26%, which is quite impressive.
The Earnings Per Share has been growing by 13.44% on average over the past years. This is quite good.
Looking at the last year, LGND shows a very strong growth in Revenue. The Revenue has grown by 64.83%.
The Revenue has been growing slightly by 6.80% on average over the past years.
EPS 1Y (TTM)25.26%
EPS 3Y-3.83%
EPS 5Y13.44%
EPS Q2Q%67.93%
Revenue 1Y (TTM)64.83%
Revenue growth 3Y-15.51%
Revenue growth 5Y6.8%
Sales Q2Q%67.71%
3.2 Future
Based on estimates for the next years, LGND will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.25% on average per year.
Based on estimates for the next years, LGND will show a very strong growth in Revenue. The Revenue will grow by 21.75% on average per year.
EPS Next Y35.02%
EPS Next 2Y18.34%
EPS Next 3Y20.06%
EPS Next 5Y16.25%
Revenue Next Year57.16%
Revenue Next 2Y25.98%
Revenue Next 3Y23.91%
Revenue Next 5Y21.75%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 27.48, which means the current valuation is very expensive for LGND.
LGND's Price/Earnings ratio is a bit cheaper when compared to the industry. LGND is cheaper than 78.65% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.39. LGND is around the same levels.
With a Price/Forward Earnings ratio of 25.05, LGND can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Forward Earnings ratio of LGND indicates a somewhat cheap valuation: LGND is cheaper than 74.48% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.84, LGND is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.48 | ||
| Fwd PE | 25.05 |
4.2 Price Multiples
LGND's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. LGND is cheaper than 77.08% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, LGND is valued a bit cheaper than the industry average as 74.48% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 128.17 | ||
| EV/EBITDA | 50.74 |
4.3 Compensation for Growth
LGND's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
LGND has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as LGND's earnings are expected to grow with 20.06% in the coming years.
PEG (NY)0.78
PEG (5Y)2.05
EPS Next 2Y18.34%
EPS Next 3Y20.06%
5. Dividend
5.1 Amount
No dividends for LGND!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
200.33
+1.92 (+0.97%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners106.5%
Inst Owner Change87.96%
Ins Owners1.62%
Ins Owner Change-1.3%
Market Cap3.94B
Revenue(TTM)251.23M
Net Income(TTM)48.58M
Analysts84.62
Price Target242.25 (20.93%)
Short Float %5.77%
Short Ratio5.64
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.83%
Min EPS beat(2)10.36%
Max EPS beat(2)57.31%
EPS beat(4)4
Avg EPS beat(4)19.98%
Min EPS beat(4)4.63%
Max EPS beat(4)57.31%
EPS beat(8)8
Avg EPS beat(8)37.45%
EPS beat(12)12
Avg EPS beat(12)53.58%
EPS beat(16)15
Avg EPS beat(16)61.91%
Revenue beat(2)2
Avg Revenue beat(2)25.66%
Min Revenue beat(2)6.44%
Max Revenue beat(2)44.89%
Revenue beat(4)4
Avg Revenue beat(4)18.43%
Min Revenue beat(4)6.44%
Max Revenue beat(4)44.89%
Revenue beat(8)8
Avg Revenue beat(8)17.31%
Revenue beat(12)11
Avg Revenue beat(12)12.65%
Revenue beat(16)14
Avg Revenue beat(16)16.25%
PT rev (1m)29.69%
PT rev (3m)29.69%
EPS NQ rev (1m)6.27%
EPS NQ rev (3m)-23.87%
EPS NY rev (1m)10.1%
EPS NY rev (3m)10.15%
Revenue NQ rev (1m)0.29%
Revenue NQ rev (3m)-10.5%
Revenue NY rev (1m)19.55%
Revenue NY rev (3m)19.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.48 | ||
| Fwd PE | 25.05 | ||
| P/S | 15.69 | ||
| P/FCF | 128.17 | ||
| P/OCF | 123.53 | ||
| P/B | 4.15 | ||
| P/tB | 9.64 | ||
| EV/EBITDA | 50.74 |
EPS(TTM)7.29
EY3.64%
EPS(NY)8
Fwd EY3.99%
FCF(TTM)1.56
FCFY0.78%
OCF(TTM)1.62
OCFY0.81%
SpS12.77
BVpS48.28
TBVpS20.77
PEG (NY)0.78
PEG (5Y)2.05
Graham Number88.99
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.29% | ||
| ROE | 5.11% | ||
| ROCE | 1.99% | ||
| ROIC | 1.58% | ||
| ROICexc | 2.92% | ||
| ROICexgc | 9.48% | ||
| OM | 11.48% | ||
| PM (TTM) | 19.34% | ||
| GM | 94.27% | ||
| FCFM | 12.24% |
ROA(3y)0.61%
ROA(5y)1.2%
ROE(3y)0.46%
ROE(5y)1.58%
ROIC(3y)1.12%
ROIC(5y)1.78%
ROICexc(3y)1.91%
ROICexc(5y)2.67%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)1.42%
ROCE(5y)2.25%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-16.87%
ROICexc growth 5YN/A
OM growth 3Y-21.5%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.37%
GM growth 5Y0.62%
F-Score5
Asset Turnover0.17
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.47 | ||
| Debt/FCF | 14.48 | ||
| Debt/EBITDA | 7.07 | ||
| Cap/Depr | 3.38% | ||
| Cap/Sales | 0.46% | ||
| Interest Coverage | 96.15 | ||
| Cash Conversion | 50.63% | ||
| Profit Quality | 63.32% | ||
| Current Ratio | 24.69 | ||
| Quick Ratio | 24.3 | ||
| Altman-Z | 5.86 |
F-Score5
WACC9.38%
ROIC/WACC0.17
Cap/Depr(3y)71.95%
Cap/Depr(5y)50.12%
Cap/Sales(3y)19.71%
Cap/Sales(5y)12.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.26%
EPS 3Y-3.83%
EPS 5Y13.44%
EPS Q2Q%67.93%
EPS Next Y35.02%
EPS Next 2Y18.34%
EPS Next 3Y20.06%
EPS Next 5Y16.25%
Revenue 1Y (TTM)64.83%
Revenue growth 3Y-15.51%
Revenue growth 5Y6.8%
Sales Q2Q%67.71%
Revenue Next Year57.16%
Revenue Next 2Y25.98%
Revenue Next 3Y23.91%
Revenue Next 5Y21.75%
EBIT growth 1Y64.02%
EBIT growth 3Y-33.67%
EBIT growth 5YN/A
EBIT Next Year652.88%
EBIT Next 3Y145.93%
EBIT Next 5Y79.19%
FCF growth 1Y-61.26%
FCF growth 3Y10.8%
FCF growth 5YN/A
OCF growth 1Y-66.41%
OCF growth 3Y7.19%
OCF growth 5YN/A
LIGAND PHARMACEUTICALS / LGND FAQ
What is the ChartMill fundamental rating of LIGAND PHARMACEUTICALS (LGND) stock?
ChartMill assigns a fundamental rating of 6 / 10 to LGND.
Can you provide the valuation status for LIGAND PHARMACEUTICALS?
ChartMill assigns a valuation rating of 5 / 10 to LIGAND PHARMACEUTICALS (LGND). This can be considered as Fairly Valued.
How profitable is LIGAND PHARMACEUTICALS (LGND) stock?
LIGAND PHARMACEUTICALS (LGND) has a profitability rating of 7 / 10.
What is the valuation of LIGAND PHARMACEUTICALS based on its PE and PB ratios?
The Price/Earnings (PE) ratio for LIGAND PHARMACEUTICALS (LGND) is 27.48 and the Price/Book (PB) ratio is 4.15.
Can you provide the expected EPS growth for LGND stock?
The Earnings per Share (EPS) of LIGAND PHARMACEUTICALS (LGND) is expected to grow by 35.02% in the next year.